Associate Director Of Regulatory Affairs - Cell Therapy

Associate Director of Regulatory Affairs - Cell TherapyOur 3 Core Values
Integrity
Initiative
What You’ll DoThe Associate Director of Regulatory Affairs will support the regulatory strategy and execution for clinical trials conducted under FDA/EMA/Other Regulatory agencies regulations. This role is responsible for preparing, submitting, and maintaining regulatory documents and ensuring compliance with all applicable laws and guidelines. The ideal candidate will demonstrate strong attention to detail, analytical skills, and knowledge of FDA/EMA/HealthCanada/MHRA requirements for investigational products.
Key Responsibilities
Assist in the preparation, review, and submission of INDs, amendments, and other regulatory filings.
Monitor regulatory changes and communicate updates to relevant teams to ensure ongoing compliance.
Coordinate with internal departments and external partners to gather necessary documentation for regulatory submissions.
Maintain accurate records of regulatory correspondence and submissions.
Support audits and inspections by regulatory authorities.
Qualifications
Bachelor’s degree in life sciences, pharmacy, or a related field;
advanced degree preferred.
3-5 years of experience in regulatory affairs within the biopharmaceutical industry.
Familiarity with FDA/EMA/HealthCanada/MHRA regulations, clinical trial processes, and regulatory submission requirements.
Strong written and verbal communication skills.
Excellent organizational and project management abilities.
Preferred Skills
Familiarity with eCTD submissions and regulatory software tools.
Ability to work effectively in a collaborative, fast-paced environment.
Attention to detail and analytical problem-solving skills.
About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non‑specific activation. NXC‑201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC‑201 is being evaluated in the U.S. multi‑center study for relapsed/refractory AL Amyloidosis NEXICART‑2 (NCT06097832), with a potentially registrational design. NXC‑201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
#J-18808-Ljbffr